ClinicalTrials.gg
WithdrawnNCT06785194Updated Oct 16, 2026

Revive Toric RWE Study

An observational study in Astigmatism, sponsored by Bausch & Lomb Incorporated. Withdrawn at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Observational

Why this study was withdrawn
Lens manufacturing has been postponed
Updated Oct 16, 2026Now WithdrawnStart date moved+3 moreGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

This is a post-market observational clinical investigation. The objective of this observational study is to evaluate the visual performance and HCP satisfaction of REVIVE samfilcon B custom toric contact lenses.

02

Conditions studied

  • Astigmatism

Browse trials for

03

In context

Astigmatism

417 studies on the registry are indexed under Astigmatism; 50 are open to participants now.

Browse Astigmatism studies →

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.

First submitted after Bausch & Lomb Incorporated became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patient population at study site locations

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18 years or older on the date the ICF is signed
  2. Have the capacity to read, understand, and provide written voluntary
  3. Have physiologically normal anterior segments not exhibiting biomicroscopy findings
  4. Have no active ocular disease or allergic conjunctivitis
  5. Not be using any topical ocular medications
  6. Be willing and able to follow instructions
  7. Have signed a statement of informed consent
  8. Be an experienced soft contact lens wearer (have previously used soft contact lenses)
  9. Meet the indications per the Instructions for Use (IFU) and have a suitable prescription for treatment with the device

Exclusion criteria

Exclusion Criteria:

  1. Is participating in another research study
  2. Is considered by the Investigator to not be a suitable candidate for participation
  3. Is not eligible for treatment with the study lens per the IFU ()
  4. Has had previous ocular surgery
  5. Is taking/using ocular, systemic, or topical medications that, in the Investigator's opinion, could potentially affect ocular physiology or lens/solution performance
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • REVIVE samfilcon B custom toric contact lenses

    REVIVE samfilcon B custom toric contact lenses

    Device: REVIVE samfilcon B custom toric contact lenses

Interventions

  • DeviceREVIVE samfilcon B custom toric contact lenses

    REVIVE samfilcon B custom toric contact lenses

06

What researchers measure

Primary outcomes

  1. Investigator overall satisfaction as assessed by the Investigator Survey

    (completed by the Investigator for each subject at 14 days ± 3 days after the final dispensing/refinement visit)

    Time frame: Assessed 14 days ± 3 days after the final dispensing/refinement visit

07

Study locations

3 sites
  • Site 101
    Orange Park, Florida 32073, United States
  • Site 102
    Orange Park, Florida 32073, United States
  • Site 103
    Canton, Georgia 30114, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Mar 2026; primary completion for Mar 2026, 0 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start May 2026 → Mar 2026, primary completion Jul 2026 → Mar 2026 and completion Jul 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 21, 2025
StartEst.
Mar 2026was May 2026
Primary completionEst.
Mar 2026was Jul 2026
CompletionEst.
Mar 2026was Jul 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Lens manufacturing has been postponed
changed Oct 16, 2026
Start date
May 2026→Mar 2026
Oct 16, 2026
Primary completion
Jul 2026→Mar 2026
Oct 16, 2026
Study completion
Jul 2026→Mar 2026
Oct 16, 2026
Enrollment
30 (estimated)→0 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Withdrawn
    Why stopped Lens manufacturing has been postponed
    Start date May 2026→Mar 2026
    Primary completion Jul 2026→Mar 2026
    Study completion Jul 2026→Mar 2026
    Enrollment 30 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06785194
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Mar 2026 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion